Literature DB >> 11076824

Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness.

C Sticherling1, H Oral, J Horrocks, S P Chough, R L Baker, M H Kim, K Wasmer, F Pelosi, B P Knight, G F Michaud, S A Strickberger, F Morady.   

Abstract

BACKGROUND: Atrial fibrillation (AF) shortens the atrial effective refractory period (ERP) and predisposes to further episodes of AF. The acute changes in atrial refractoriness may be related to tachycardia-induced intracellular calcium overload. The purpose of this study was to determine whether digoxin, which increases intracellular calcium, potentiates the acute effects of AF on atrial refractoriness in humans. METHODS AND
RESULTS: In 38 healthy adults, atrial ERP was measured at basic drive cycle lengths (BDCLs) of 350 and 500 ms after autonomic blockade. Nineteen patients had been treated with digoxin for 2 weeks. After a several-minute episode of AF, atrial ERP was measured serially at alternating BDCLs. Compared with pre-AF ERPs, the first post-AF ERPs were significantly shorter in both the digoxin and the control groups (P:<0.001). The post-AF ERP at a BDCL of 350 ms shortened to a greater degree in the digoxin group (37+/-16 ms) than in the control group (20+/-13 ms, P:<0.001); similar changes occurred at a BDCL of 500 ms. During post-AF determinations of the atrial ERP, secondary AF episodes occurred significantly more often in the digoxin group (32% versus 16%; P:<0. 04).
CONCLUSIONS: After a brief episode of AF, digoxin augments the shortening that occurs in atrial refractoriness and predisposes to the reinduction of AF. These effects occur in the setting of autonomic blockade and therefore are more likely to be due to the effects of digoxin on intracellular calcium than to its vagotonic effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076824     DOI: 10.1161/01.cir.102.20.2503

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 2.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

Review 3.  Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors:  Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 4.  Atrial Fibrillation: The New Epidemic of the Ageing World.

Authors:  Wilbert S Aronow; Maciej Banach
Journal:  J Atr Fibrillation       Date:  2009-04-01

Review 5.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

6.  Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

Authors:  C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

7.  Predictors of atrial fibrillation recurrence in patients with long-lasting atrial fibrillation.

Authors:  Michalis Efremidis; Ioannis P Alexanian; Dimitrios Oikonomou; Dimitrios Manolatos; Konstantinos P Letsas; Loukas K Pappas; Gerasimos Gavrielatos; Maria Vadiaka; Constantinos C Mihas; Gerasimos S Filippatos; Antonios Sideris; Fotios Kardaras
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

8.  Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.

Authors:  Nayoung Kim; Hwa Young Yim; Ningning He; Cheol-Jung Lee; Ju Hyun Kim; Jin-Sung Choi; Hye Suk Lee; Somin Kim; Euna Jeong; Mee Song; Sang-Min Jeon; Woo-Young Kim; Gordon B Mills; Yong-Yeon Cho; Sukjoon Yoon
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.